Finally, we leveraged the APOB- and MTTP-mutant organoids to establish a CRISPR-based screening platform to identify steatosis modulators/targets and to evaluate NAFLD risk genes. This evidence concerns the gene MT-TP and metabolic dysfunction-associated steatotic liver disease.